65,437 trials
Breast Cancer
Primary: Frequency of Breast Imaging Assessment Reporting and Data System (BI-RADS) "0" Call-back in Mammography vs Breast Imaging Assessment Reporting and Data System (BI-RADS)…
Atrial Fibrillation · Stroke
Primary: Number of Participants Who Prescribed Oral Anticoagulants (OAC) According to the Number of Decision Aid Diagrams — 400; 406 participants — p=0.83
Rheumatoid Arthritis
Primary: Regression Coefficient Between Change in Fatigue Score as Measured by the Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F) at Week 12 and Change…
Multiple Sclerosis
Primary: The Number of T1-Gadolinium Enhancing Lesions During Months 7-9 — 0.42; 0.38; 0.82; 0.45 Number of lesions
Hepatitis C, Chronic
Primary: Percentage of Participants With Sustained Virological Response (SVR) at 24 Weeks After End of Treatment — 39.5; 34.9 percentage of participants — p=0.6746
Schizophrenia
Primary: Work Quality — 3.01; 3.23; 3.33 scores on a scale
End-stage Renal Disease
Primary: State-Trait Anxiety Inventory — 42.1; 37.8; 40.6; 34.8 units on a scale
Pelvic Organ Prolapse
Primary: Percent of Subjects With an ICS (International Incontinence Society) POP-Q (Pelvic Organ Prolapse Quantification System) Stage of </= Stage I in the Posterior…
Stroke · Myocardial Infarction · Diabetes
Primary: Recurrent Fatal or Non-fatal Stroke, or Fatal or Non-fatal Myocardial Infarction — 175; 228 participants — p=.0067
Post-Menopausal Osteoporosis
Primary: Percentage of Participants Current Daily or Weekly Bisphosphonate Users in Part A Who Answer 'Yes' to Any of the Questions in the Candidate Identification Questionnaire…
Lymphoma, Non-Hodgkin · Hodgkin Disease
Primary: Maximum Tolerated Dose (MTD) of IV AMD3100 + G-CSF in Mobilization of Peripheral Blood Stem Cell in Patients With Lymphoma (Phase I Only) — 400 micrograms/kilograms
Primary Open Angle Glaucoma (POAG)
Primary: Proportion of Eyes With Intraocular Pressure (IOP) Reduction of ≥ 20% at 12 Months Postoperatively Who Were on Fewer or the Same Number of Ocular Hypotensive Medications…
Gastric Cancer, Gastroesophageal Junction Cancer
Primary: Simple Kappa Coefficient of Human Epidermal Growth Factor Receptor 2 (HER-2) Status Between Local and Centralized Laboratory Assessments — 0.69 kappa coefficient…
Trigger Finger
Primary: Difference in Visual-analog Score (VAS) for Anticipated Pain Prior to Injection and Actual Pain After Injection — 1.6; 2.8 units on a scale
Schizophrenia
Primary: Percentage of Participants Who Experience at Least One Treatment-Emergent Adverse Event (TEAE) After 7 Days of Dosing — 57.1; 87.5; 71.4; 75.0 percentage of participants